Rapamycin, discovered in the 1970s from soil bacteria on Easter Island, was initially developed as an immunosuppressant for organ transplant patients. However, it has since become the subject of intense interest in the field of anti-aging research. Rapamycin targets the mTOR pathway, a crucial regulator of aging and metabolism, and has shown potential in preventing or slowing down age-related diseases like Alzheimer’s, cancer, and heart disease.
But why, despite its promising benefits, has Rapamycin been kept mostly out of the public's hands? As a prescription-only drug, it's been tightly controlled and dominated by pharmaceutical companies, making it both expensive and inaccessible to the average person. It's a situation that smacks of a conspiracy, a secret kept from us to maintain profits for the few.